Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Everest Medicines Ltd. ( (HK:1952) ) just unveiled an update.
Everest Medicines shareholders approved all resolutions at an extraordinary general meeting held virtually on 24 February 2026, including ratification of a Commercialization Service Agreement and a grant of 530,303 awards to executive director Yifang Wu under the Pre-IPO ESOP. Investors also backed a new 2026 Share Scheme with a 10% mandate limit and a 0.5% sublimit for service providers, reinforcing the company’s use of equity incentives to retain key talent and align external partners, which may influence future dilution and governance dynamics for existing shareholders.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$36.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Limited is a biopharmaceutical company listed in Hong Kong that focuses on developing and commercializing innovative medicines. The company operates through share-based incentive schemes and commercial partnerships to support its growth and align stakeholders with its long-term strategy.
Average Trading Volume: 3,362,912
Technical Sentiment Signal: Sell
Current Market Cap: HK$13.88B
For a thorough assessment of 1952 stock, go to TipRanks’ Stock Analysis page.